Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 35 (Search time: 0.002 seconds).
previous
1
2
3
4
next
Item hits:
Preview
Issue Date
Title
Author(s)
2014
Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepoint
Branford, S.
;
Ross, D.
;
Yeung, D.
;
Braley, J.
;
Hughes, T.
;
56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California)
2010
Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial
Yeung, D.
;
Osborn, M.
;
White, D.
;
Branford, S.
;
Haswell, L.
;
Slader, C.
;
Issa, S.
;
Hiwase, D.
;
Hertzberg, M.
;
Schwarer, A.
;
Filshie, R.
;
Arthur, C.
;
Kwan, Y.
;
Forsyth, C.
;
Ross, D.
;
Mills, A.
;
Grigg, A.
;
Hughes, T.
;
Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.)
2010
Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatment
Kim, D.
;
Kim, D.
;
Kim, S.
;
Goh, H.
;
Pane, F.
;
Hughes, T.
;
Radich, J.
;
Lin, P.
;
Saglio, G.
;
Branford, S.
;
Martinelli, G.
;
Soverini, S.
;
Hochhaus, A.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010
A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate
Branford, S.
;
Goh, H.
;
Izzo, B.
;
Beppu, L.
;
Ortmann, C.
;
Duniec, K.
;
Jin, Y.
;
Woodman, R.
;
Pane, F.
;
Kim, D.
;
Radich, J.
;
Hughes, T.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010
Detection of low level nilotinib or dasatinib resistant BCR-ABL mutations by mass spectrometry in CML patients who fail Imatinib is highly predivtive of their subsequent clonal expansion when treated with the drug for which their mutation confers resistance
Parker, W.
;
Ho, M.
;
Lawrence, R.
;
Irwin, D.
;
Scott, H.
;
Hughes, T.
;
Branford, S.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010
Towards DNA-based monitoring of therapy in chronic myeloid leukemia
Morley, A.
;
Bartley, P.
;
Ross, D.
;
Latham, S.
;
Budgen, B.
;
Branford, S.
;
Hughes, T.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010
Contrasting response of patients with chronic myeloid leukaemia (CML) and the highly imatinib resistant L248V mutation that may be related to an increased propensity of some patients to form an associated deletion mutant with increased imatinib sensitivity
Prime, H.
;
Romeo, G.
;
Phillis, S.
;
Field, C.
;
Jamison, B.
;
Prime, J.
;
Parker, W.
;
Joske, D.
;
Hughes, T.
;
Branford, S.
;
Haematology Association of Australasia Annual Meeting (2010 : Auckland, New Zealand)
2010
Limiting the variability within a BCR-ABL quantitative PCR (RQ-PCR) assay is essential for optimal concordance of results between laboratories generating BCR-ABL values on an international reporting scale
Fletcher, L.
;
Prime, J.
;
Phillis, S.
;
Jamison, B.
;
Field, C.
;
Prime, H.
;
Sullivan, B.
;
Yeoman, A.
;
Georgievski, J.
;
Parker, W.
;
Slader, C.
;
Hughes, T.
;
Branford, S.
;
Haematology Association of Australasia Annual Meeting (2010 : Auckland, New Zealand)
2014
The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment
Branford, S.
;
Yeung, D.
;
Ross, D.
;
Parker, W.
;
Braley, J.
;
Seymour, J.
;
Hughes, T.
;
56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California)
2013
PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutations
Parker, W.
;
Phillis, S.
;
Yeung, D.
;
Hughes, T.
;
Scott, H.
;
Branford, S.
;
55th American Society of Hematology Annual Meeting and Exhibition (7 Dec 2013 - 10 Dec 2013 : New Orleans, Louisiana)
Discover
Author
12
Ross, D.
12
Yeung, D.
9
Radich, J.
8
Parker, W.
6
Kim, D.
6
Phillis, S.
6
Seymour, J.
6
White, D.
5
Field, C.
5
Grigg, A.
.
next >
Subject
12
Benzamides
12
Piperazines
12
Pyrimidines
11
Leukemia, Myelogenous, Chronic, B...
10
Antineoplastic Agents
10
Humans
9
Fusion Proteins, bcr-abl
9
Imatinib Mesylate
6
Protein Kinase Inhibitors
5
Adult
.
next >
Date issued
2
2018
1
2017
1
2016
1
2015
7
2014
5
2013
1
2012
4
2011
13
2010